Mu-Hong Chen, Ya-Mei Bai, S. Tsai
2026.1.1Med
tlooto Summary
Findings from Badulescu et al.'s placebo-controlled trial reported that semaglutide, a GLP-1 receptor agonist, may improve attention and memory, although there was no significant improvement in overall depressive symptoms.
Abstract
Cognitive impairments in depression, driven by both the illness per se and low-grade systemic inflammation, markedly reduce functional capacity and quality of life among patients who suffer. Findings from Badulescu et al.'s placebo-controlled trial reported that semaglutide, a GLP-1 receptor agonist, may improve attention and memory, although there was no significant improvement in overall depressive symptoms.
Citation format
CHEN, Mu-Hong; BAI, Ya-Mei; TSAI, S. Depression, cognition, and GLP-1 receptors: Heterogeneity and therapeutic prospects. Med, 2026, 7 1(1): 100954.